These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 30128699)

  • 1. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
    Dhillon S
    Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
    Patel TS; Pogue JM; Mills JP; Kaye KS
    Future Microbiol; 2018 Jul; 13(9):971-983. PubMed ID: 29692218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
    Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
    JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
    Lee YR; Baker NT
    Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
    Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
    Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
    Wu G; Cheon E
    Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.
    Jorgensen SCJ; Rybak MJ
    Pharmacotherapy; 2018 Apr; 38(4):444-461. PubMed ID: 29427523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Update on Existing and Emerging Data for Meropenem-Vaborbactam.
    Shoulders BR; Casapao AM; Venugopalan V
    Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
    Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
    Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination.
    Cho JC; Zmarlicka MT; Shaeer KM; Pardo J
    Ann Pharmacother; 2018 Aug; 52(8):769-779. PubMed ID: 29514462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
    Albin OR; Patel TS; Kaye KS
    Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
    Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
    Zhang W; Yan CY; Li SR; Fan TT; Cao SS; Cui B; Li MY; Fan BY; Ji B; Wang L; Cui F; Cui J; Wang L; Guan Y; Wang JW
    Front Cell Infect Microbiol; 2023; 13():1093842. PubMed ID: 37207190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
    Wenzler E; Scoble PJ
    Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date.
    Herald F; Burgos RM
    Infect Drug Resist; 2023; 16():555-568. PubMed ID: 36726388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection.
    Burgos RM; Biagi MJ; Rodvold KA; Danziger LH
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1007-1021. PubMed ID: 30106599
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Hackel MA; Lomovskaya O; Dudley MN; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.